These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30083702)

  • 1. HLA-B*5801 Testing to Prevent Allopurinol Hypersensitivity Syndrome: A Teachable Moment.
    Quach C; Galen BT
    JAMA Intern Med; 2018 Sep; 178(9):1260-1261. PubMed ID: 30083702
    [No Abstract]   [Full Text] [Related]  

  • 2. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
    Yeo SI
    Int J Rheum Dis; 2013 Jun; 16(3):254-7. PubMed ID: 23981744
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Ponzo MG; Miliszewski M; Kirchhof MG; Keown PA; Dutz JP
    J Cutan Med Surg; 2019; 23(6):595-601. PubMed ID: 31378082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-B*5801: a genetic susceptibility to allopurinol-induced DRESS.
    Mugwagwa AN; Fischer R; Zailan I
    Med J Aust; 2016 Mar; 204(4):159-60. PubMed ID: 26937673
    [No Abstract]   [Full Text] [Related]  

  • 5. Allopurinol-induced drug reaction with eosinophilia and systemic symptoms syndrome associated with reactivation of Epstein-Barr virus leading to secondary hemophagocytic lymphohistiocytosis in an HLA-B*5801-negative patient.
    Su T; Xiong W; Xu Y; Lu Y
    Indian J Dermatol Venereol Leprol; 2021 [SEASON]; 87(4):545-548. PubMed ID: 34219434
    [No Abstract]   [Full Text] [Related]  

  • 6. Cross-Reactions Between Allopurinol and Febuxostat.
    Lien YH; Logan JL
    Am J Med; 2017 Feb; 130(2):e67-e68. PubMed ID: 27667702
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug reaction with eosinophilia and systemic symptoms: DRESS syndrome.
    Magallanes Gamboa JÓ; Notario Barba V
    Emergencias; 2018 Jun; 30(3):207-208. PubMed ID: 29687681
    [No Abstract]   [Full Text] [Related]  

  • 8. [Allopurinol hypersensitivity syndrome. A report of two cases].
    Rodríguez-Arámbula A; Arenas-Velázquez E; Castanedo-Cázares JP; Hernández-Blanco D; Oros-Ovalle C; Torres-Álvarez B
    Rev Med Inst Mex Seguro Soc; 2016; 54(2):261-4. PubMed ID: 26960055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case-control clinical study.
    Cheng L; Xiong Y; Qin CZ; Zhang W; Chen XP; Li J; Zhou HH
    Br J Dermatol; 2015 Aug; 173(2):555-8. PubMed ID: 26104483
    [No Abstract]   [Full Text] [Related]  

  • 10. [HLA-B58.01 and allopurinol hypersensitivity renal vasculitis in a Chinese patient].
    Mariette F; Scarfoglière V; Giot M; Basire A; Rouby F; Daniel L; Jourde-Chiche N
    Rev Med Interne; 2022 Jul; 43(7):436-439. PubMed ID: 35606203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allopurinol-induced drug rash with eosinophilia and systemic symptoms mimicking acute generalized exanthematous pustulosis.
    Huang YC; Shih PY; Chin SY; Chiang YY
    J Dermatol; 2012 Dec; 39(12):1077-8. PubMed ID: 22901319
    [No Abstract]   [Full Text] [Related]  

  • 12. A Personalized Medicine Approach to Guide Allopurinol Use and Prevent Serious Adverse Events: Ethnicity Is Not a Proxy for Genetics.
    Ikediobi O
    Clin Pharmacol Ther; 2021 Oct; 110(4):852-854. PubMed ID: 33330976
    [No Abstract]   [Full Text] [Related]  

  • 13. Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.
    Yu KH; Yu CY; Fang YF
    Int J Rheum Dis; 2017 Sep; 20(9):1057-1071. PubMed ID: 28857441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response.
    Yun J; Mattsson J; Schnyder K; Fontana S; Largiadèr CR; Pichler WJ; Yerly D
    Clin Exp Allergy; 2013 Nov; 43(11):1246-55. PubMed ID: 24152157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allopurinol hypersensitivity syndrome.
    Yaseen W; Auguste B; Zipursky J
    CMAJ; 2023 Apr; 195(13):E483. PubMed ID: 37011932
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout.
    Plumpton CO; Alfirevic A; Pirmohamed M; Hughes DA
    Rheumatology (Oxford); 2017 Oct; 56(10):1729-1739. PubMed ID: 28957559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allopurinol Induced DRESS Syndrome.
    Pawar P; Gupta VA; Karnik ND; Vaidya M; Khopkar U
    J Assoc Physicians India; 2014 Nov; 62(11):63-5. PubMed ID: 26281488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug eruptions induced by allopurinol associated with HLA-B*5801.
    Zeng M; Zhang M; Liu F; Yan W; Kong Q; Sang H
    Indian J Dermatol Venereol Leprol; 2015; 81(1):43-5. PubMed ID: 25566896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allopurinol hypersensitivity syndrome in patients with hematological malignancies: characteristics and clinical outcomes.
    Min HK; Lee B; Kwok SK; Ju JH; Kim WU; Park YM; Park SH
    Korean J Intern Med; 2015 Jul; 30(4):521-30. PubMed ID: 26161019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allopurinol overuse in asymptomatic hyperuricemia: a teachable moment.
    Carnovale C; Venegoni M; Clementi E
    JAMA Intern Med; 2014 Jul; 174(7):1031-2. PubMed ID: 24798999
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.